ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation, Confirmation, and Cohort Expansion Study of Nemtabrutinib in Hematologic Malignancies"

177 views
June 14, 2023
0 Comments
Login to view comments. Click here to Login